As the company enter fiscal 2021, the company believes that company well prepared to meet demand arising from an expected recovery from the effects of COVID-19 and company remain encouraged by the long-term growth trajectory of products across the surgical and wound divisions. As conditions continue to evolve, the precise depth and duration of COVID-19's impact on the operations remains uncertain and as a result Misonix is not providing fiscal year 2021 financial guidance at this time.